Meticulous Research®—a leading global market research company, published a research report titled ‘Recombinant Coagulation Factors Market by Type (Factor VIII, Factor IX) Source (CHO, HEK) Application (Hemophilia A, Hemophilia B, Von Willebrand Disease) End User (Hospitals & Clinics, Clinical Research Laboratories) Geography - Global Forecast to 2030.’
In the latest publication by Meticulous Research®, the recombinant coagulation factors market is forecasted to achieve $24.21 billion by 2030 , with a projected compound annual growth rate (CAGR) of 8.6% during the forecast period. Driving this growth are factors such as the increasing prevalence of hemophilia and other bleeding disorders, growing research and development (R&D) for coagulation factors, rising awareness about the benefits of recombinant coagulation factors, and increasing prophylactic treatment for hemophilia worldwide. Additionally, potential emerging economies and rising healthcare expenditure are expected to offer significant growth opportunities for the market.
However, challenges such as the high cost of recombinant factors compared to plasma-derived ones, limited accessibility and availability of recombinant clotting factors in developing and underdeveloped countries, manufacturing challenges, stringent regulatory requirements, lack of reimbursement in some countries, and lack of awareness among patients are expected to restrain market growth.
The report segments the recombinant coagulation factors market by type (Recombinant Factors VIII, Recombinant Factor IX, and Other Types), source (Chinese Hamster Ovary [CHO] Cell Line, Human Embryonic Kidney [HEK] Cell Line, and Other Sources), application (Hemophilia A, Hemophilia B, and Other Applications), end user (Hospitals & Clinics and Clinical Research Laboratories), and geography. It provides a comprehensive analysis of industry competitors and evaluates the market at regional and country levels.
Key Insights:
The recombinant factor VIII segment is expected to dominate the market in 2023, driven by the rising prevalence of bleeding disorders and the higher adoption of recombinant factor VIII since its establishment in the market in 1992.
The Chinese hamster ovary (CHO) cell line segment is anticipated to hold the largest share of the market in 2023, attributed to the higher utilization of CHO cell lines and their advantages in generating glycosylation profiles, reproducibility, and ease of manipulation.
The hemophilia A segment is projected to account for the largest share of the market in 2023, owing to the high prevalence of hemophilia A and increased adoption of recombinant coagulation factors for its treatment.
The hospitals & clinics segment is expected to hold the largest share of the market in 2023, driven by the high utilization of recombinant coagulation factors in these settings and increased awareness among healthcare professionals.
The report also analyzes major geographies, including North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, providing comprehensive market insights.
Key Players:
Major players in the recombinant coagulation factors market include Baxter International Inc., Grifols, S.A., CSL Limited, Octapharma AG, Novo Nordisk A/S, Biogen Inc., Bayer AG, Kedrion S.p.A., Emergent BioSolutions, and Pfizer Inc.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=1254
Key Questions Addressed:
What are the high-growth market segments in terms of type, source, application, end user, and region/country?
What was the historical market size for recombinant coagulation factors globally?
What are the market forecasts and estimates for the period 2023–2030?
What are the major drivers, restraints, and opportunities in the global recombinant coagulation factors market?
Who are the major players in the market, and what is the competitive landscape like?
What are the recent developments and strategies adopted by major players?
What are the geographical trends and high-growth regions/countries?
ContactUs:
MeticulousResearch®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Connect with us on Twitter- https://twitter.com/MeticulousR123